Aspergillus spp. invasive external otitis: favourable outcome with a medical approach. (May 2016)

• Record Type: Journal Article
• Authors: Marchionni, E.; Parize, P.; Lefevre, A.; Vironneau, P.; Bougnoux, M.E.; Poiree, S.; Coignard-Biehler, H.; DeWolf, S.E.; Amazzough, K.; Barchiesi, F.; Jullien, V.; Alanio, A.; Garcia-Hermoso, D.; Wassef, M.; Kania, R.; Lortholary, O.; Lanternier, F.
• Is Part Of: Clinical microbiology and infection. Volume 22:Number 5(2016)
• Page Start: 434
• Page End: 437
• Publication Date: 2016-05
• Subjects: Aspergillus spp. -- diabetes mellitus -- invasive -- otitis -- voriconazole; Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1016/j.cmi.2015.12.027
• Languages: English
• ISSNs: 1198-743X

Abstract

Abstract: Aspergillus spp. invasive external otitis (IEO) is a rare infection. We performed a seven-year, single-centre retrospective study from 2007 to 2014 including all patients with proven Aspergillus spp. IEO. Twelve patients were identified. All patients had a poorly controlled diabetes mellitus and one underwent solid organ transplant. The most frequently isolated species was Aspergillus flavus ( n = 10) and voriconazole was the first-line therapy in all cases, with a median length of treatment of 338.5 days (158–804 days). None of the patients underwent extensive surgery. The clinical outcome was excellent. However, otological sequelae were reported, including hearing impairment ( n = 7) and facial palsy ( n = 3).